Lenalidomide 25mg Capsule

Lenalidomide 25mg Capsule contains 25mg lenalidomide, an oral immunomodulatory anticancer medicine used in approved hematology-oncology treatment. Generic lenalidomide 25mg is marketed as an alternative to Revlimid® 25mg, with manufacturer and packaging varying by product. Local search terms include Lenalidomid 25 mg Hartkapseln, lénalidomide 25 mg, 레날리도마이드 25mg and леналидомид 25 мг.

Product Information

Generic Name

Lenalidomide

Strength

25mg

Dosage Form

Hard Capsule

Route

Oral

Drug Class

Immunomodulatory Antineoplastic Agent

Reference Brand

Revlimid® 25mg

Main Therapeutic Area

Hematologic Oncology

Prescription Status

Prescription medicine

Manufacturer

Varies by generic product

Pack Size

Varies by market and manufacturer

Generic Revlimid® 25mg

Revlimid® is the reference medicine containing lenalidomide. Generic lenalidomide 25mg products contain the same active ingredient but can differ in manufacturer, excipients, capsule markings, appearance and packaging.

France's current public medicines database explicitly places Lenalidomide Accord 25mg and multiple other 25mg products in the generic group equivalent to Revlimid 25mg.

Commercial Availability

High-intent searches include lenalidomide 25mg price, lenalidomide 25mg capsule, generic Revlimid 25mg, Revlimid 25mg capsule, lenalidomide 25mg pharmacy, lenalidomide 25mg cost and lenalidomide 25mg prescription.

UK, Australian and French sources currently document multiple 25mg lenalidomide products. The UK medicines database lists active 25mg hard-capsule products from manufacturers including Biocon, Thornton & Ross, Amarox and Teva, while Australia has registered generic products alongside Revlimid.

Lenalidomide is used in approved treatment regimens for multiple myeloma and selected hematologic cancers. Current U.S. labeling includes multiple myeloma, maintenance after autologous hematopoietic stem-cell transplantation and certain MDS, MCL, follicular lymphoma and marginal-zone lymphoma settings; exact indications differ by country.

Lenalidomide is a high-risk prescription oncology medicine. Major safety concerns include embryo-fetal toxicity, blood-cell abnormalities and venous or arterial thromboembolism. U.S. labeling includes restricted-distribution requirements through the Lenalidomide REMS program.

Treatment must be prescribed and monitored by an appropriate oncology professional. The capsule should be swallowed whole and not opened, broken or chewed.